Share on StockTwits

Boston Scientific Corp. (NYSE:BSX) was upgraded by Piper Jaffray from a “neutral” rating to an “overweight” rating in a research note issued on Tuesday, reports. The firm currently has a $18.00 price objective on the stock, up from their previous price objective of $12.00. Piper Jaffray’s target price indicates a potential upside of 28.76% from the stock’s previous close.

BSX has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific Corp. in a research note to investors on Tuesday, January 14th. They now have a $14.00 price target on the stock. Separately, analysts at Barclays raised their price target on shares of Boston Scientific Corp. from $13.00 to $14.00 in a research note to investors on Thursday, January 9th. They now have an “overweight” rating on the stock. Finally, analysts at BTIG Research initiated coverage on shares of Boston Scientific Corp. in a research note to investors on Tuesday, January 7th. They set a “buy” rating on the stock. Twelve investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Boston Scientific Corp. has an average rating of “Hold” and an average price target of $11.59.

Shares of Boston Scientific Corp. (NYSE:BSX) traded up 3.48% on Tuesday, hitting $13.98. The stock had a trading volume of 20,088,072 shares. Boston Scientific Corp. has a 52-week low of $6.72 and a 52-week high of $14.02. The stock’s 50-day moving average is $12.1 and its 200-day moving average is $11.5. The company’s market cap is $18.666 billion. Boston Scientific Corp. also was the recipient of unusually large options trading on Tuesday. Stock investors acquired 35,723 call options on the stock. This represents an increase of 454% compared to the average volume of 6,451 call options.

Boston Scientific Corp. (NYSE:BSX) last issued its quarterly earnings data on Thursday, October 24th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.08. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the previous year, the company posted $0.16 earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. Analysts expect that Boston Scientific Corp. will post $0.45 EPS for the current fiscal year.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.